Brief reports
Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia

https://doi.org/10.1016/j.amjcard.2004.12.064Get rights and content

The inhibition of cholesteryl ester transfer protein (CETP) has recently been shown to effectively increase high-density lipoprotein (HDL) cholesterol. This study examined the use of the CETP inhibitor JTT-705 combined with pravastatin. In a randomized, double-blind, placebo-controlled trial, 155 patients with type II dyslipidemia using pravastatin 40 mg were treated with placebo or JTT-705 300 or 600 mg. Four weeks of treatment with JTT-705 600 mg led to a 30% decrease in CETP activity (p <0.001), a 28% increase in HDL cholesterol (p <0.001), and a 5% decrease in low-density lipoprotein cholesterol (p <0.03). Combination therapy using JTT-705 and pravastatin effectively increases HDL cholesterol levels and is safe and well tolerated up to 4 weeks of administration.

References (10)

There are more references available in the full text version of this article.

Cited by (176)

  • HDL and Endothelium

    2018, Endothelium and Cardiovascular Diseases: Vascular Biology and Clinical Syndromes
  • Reverse Cholesterol Transport in HDL Metabolism: Relevance to Atherosclerosis Progression and Cardiovascular Diseases

    2017, The HDL Handbook: Biological Functions and Clinical Implications: Third Edition
  • Learning by Experience: Examples of Translational Processes in the Cardiovascular Field

    2015, Principles of Translational Science in Medicine: From Bench to Bedside: Second Edition
View all citing articles on Scopus

This study was supported by a grant from AKROS Pharma Inc., Princeton, New Jersey. Dr. Klerkx was supported by a grant from the Dutch Heart Foundation, Amsterdam, The Netherlands (NHS 2000.073 and NHS 2003B191).

View full text